Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 15Neoplasms 8cyclopia sequence 7Prostatic Neoplasms 7Polycystic Ovary Syndrome 5Fatigue 5Lung Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Pain 3Obesity 3Neoplasm Metastasis 3Multiple Myeloma 3Leiomyoma 3Vomiting 2Urinary Bladder Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasms, Plasma Cell 2Nausea 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Insulin Resistance 2Infertility 2Hyperandrogenism 2Hematologic Diseases 2Depression 2Burkitt Lymphoma 2Weight Loss 1

Interventions

eculizumab 3ravulizumab 2fludarabine 2Cyclophosphamide 2ublituximab 1thymoglobulin 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Sugars 1Rituximab 1Prednisone 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Melphalan 1LFB-R603 1Immunoglobulins, Intravenous 1Etoposide 1Data Collection 1Cytarabine 1Carmustine 1Antilymphocyte Serum 1Alleles 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuromyelitis Optica × Sugars × Clear all
NCT02166346 2018-04-17

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Johns Hopkins University

Phase 2 Completed
24 enrolled 10 charts

Myelitis, Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon âš¡